- Home
- EVRG vs INCY Comparison
EVRG vs INCY Comparison
Compare EVRG & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVRG | INCY |
|---|---|---|
| Founded | 2017 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3B | 17.0B |
| IPO Year | 2017 | 1994 |
Fundamental Metrics
Financial Performance| Metric | EVRG | INCY |
|---|---|---|
| Price | $81.34 | $98.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 21 |
| Target Price | $87.38 | ★ $103.52 |
| AVG Volume (30 Days) | ★ 1.3M | 1.3M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.42% | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | ★ 3.66 | 1.47 |
| Revenue | ★ $5,961,600,000.00 | $3,394,635,000.00 |
| Revenue This Year | $6.52 | $10.44 |
| Revenue Next Year | $7.12 | $10.99 |
| P/E Ratio | ★ $22.23 | $67.39 |
| Revenue Growth | 1.95 | ★ 13.67 |
| 52 Week Low | $64.75 | $57.77 |
| 52 Week High | $85.27 | $112.29 |
Technical Indicators
Market Signals| Indicator | EVRG | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 48.30 | 59.59 |
| Support Level | $80.27 | $82.66 |
| Resistance Level | $83.53 | $99.92 |
| Average True Range (ATR) | 1.31 | 2.91 |
| MACD | -0.10 | 0.28 |
| Stochastic Oscillator | 39.19 | 62.34 |
Price Performance
Historical ComparisonAbout EVRG Evergy Inc.
Evergy is a regulated electric utility serving eastern Kansas and western Missouri. Major operating subsidiaries include Evergy Metro, Evergy Kansas Central, Evergy Missouri West, and Evergy Transmission. The utility has a combined rate base of more than $20 billion, about half in Kansas and the rest split between Missouri and interstate transmission. Evergy is one of the largest wind energy suppliers in the US.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.